# Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629

> **NCT00854204** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 12 (actual)

## Conditions studied

- HIV-I

## Interventions

- **DRUG:** TMC114; TMC41629

## Key facts

- **NCT ID:** NCT00854204
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00854204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00854204, "Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00854204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*